# A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid

> **NCT00418665** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 39 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Thrombocytopenia

## Interventions

- **BIOLOGICAL:** AMG 531
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00418665
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2009-03
- **Final completion:** 2010-10
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2011-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00418665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00418665, "A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00418665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*